STOCK · JNJ · NYSE
Johnson & Johnson trades under the ticker symbol JNJ on the NYSE. This page brings together its live stock price, an interactive price chart, and key fundamentals like market capitalization, 52-week range, dividend yield, and the next earnings date, with plain-English context to help you understand what the numbers mean.
Loading the live price and chart for JNJ…
Stock prices move on company earnings, growth expectations, interest rates, and overall market sentiment. Use the live chart and fundamentals as a starting point for your own research, never as a buy or sell signal.
Johnson & Johnson is a diversified healthcare company that split into two in 2023. J&J now focuses on pharmaceuticals and MedTech after spinning off its consumer health division (Kenvue). The restructuring was intended to let the faster-growing, higher-margin businesses operate without the slower consumer segment dragging on valuation.
The pharmaceutical pipeline includes cancer treatments, immunology drugs, and neuroscience. MedTech makes surgical tools, orthopedic devices, and electrophysiology equipment. Both face pricing pressure but generate strong recurring revenue from healthcare systems globally.
J&J has increased its dividend for over 60 consecutive years, making it one of the S&P 500's Dividend Kings. For income investors, that track record carries real weight.
Source: Johnson & Johnson SEC filings (10-K) and investor relations · Last reviewed June 2026
Johnson & Johnson scores 78 out of 100 (grade B) across the 4 measures we can read from its filings. Its strongest measure is profitability (grade A); its weakest is growth (grade D).
Rule-based grades derived from annual figures reported to the SEC. Descriptive, not a rating of the investment.
Johnson & Johnson grew its revenue slowly (about 2.1% a year) over the 7 years through FY2025, and profit grew even faster, so the business became more profitable as it grew. Its profit margin widened over the period. Free cash flow grew alongside profit.
Volatile. Revenue went from $81.6B in FY2018 to $94.2B in FY2025, about 2.1% a year. The top line is still expanding, the first sign the business is still in demand.
Volatile. Profit went from $16.5B in FY2016 to $26.8B in FY2025, about 5.5% a year. The business is keeping more profit over time, not less.
gross margin went from 66.8% to 67.9% (volatile); net margin went from 18.8% to 28.5% (volatile). Each dollar of sales is turning into more profit over time, often a sign of pricing power or scale.
Volatile. Free cash flow went from $15.5B in FY2016 to $19.7B in FY2025, about 2.7% a year. The profit is showing up as real cash, which is what you want to see.
Over the last 10 years the company returned about $54.1B through buybacks to shareholders. Whether that cash was spent well depends on the price paid for the stock, which this section does not judge. It shows the choices, not a verdict.
Derived from the annual figures this company reported to the SEC. What is described already happened; it is not a forecast.
Holding. Johnson & Johnson keeps about 67.9% of every sales dollar before overhead, and that share has held roughly steady over the last 7 years.
The Investment Case describes Johnson & Johnson's competitive advantages, and the risks that could erode them.
These are the quality measures the financial statements support. Several others, such as brand strength and customer concentration, need human judgment and are not measured automatically.
Historically, the company has used a mix of reinvestment, buybacks, and dividends.
On average, capital spending used about 17% of operating cash flow across 10 fiscal years (FY2016-FY2025) - a moderate share of the cash the business generated went back into it.
Reported share repurchases in 10 of the 10 fiscal years shown, totaling about $54.1B (FY2016-FY2025). The reported share count fell about 11% from FY2016 to FY2025.
Paid a per-share dividend in each of the 10 fiscal years shown (FY2016-FY2025). The annual per-share dividend did not decline year over year in that window, rising in 9 straight year-over-year changes into FY2025.
The total debt balance rose over the window: about $27.1B in FY2016 vs about $49.9B in FY2025. This describes the balance's direction, not repayments.
As of FY2025, held about $19.7B in cash and equivalents vs about $49.9B of total debt - more total debt than cash at that date.
Derived from annual figures this company reported to the SEC (EDGAR XBRL company facts). Descriptive history only: not a forecast, not a rating, not investment advice.
What has varied in Johnson & Johnson's past filings, and what to keep an eye on. Descriptive, not a forecast and not a rating.
Johnson & Johnson is a large, diversified healthcare company focused on prescription drugs and medical technology after spinning off its consumer health business (Kenvue) in 2023. The long-term question is whether a deep drug pipeline and steady medical-device demand keep funding its very long record of dividend increases as older drugs lose patent protection.
Educational analysis from public filings. This is not a recommendation to buy or sell any security.
See all our Investment Cases on Stock Watch →
Compare its behavior on the Stock Screener →
Sources: Johnson & Johnson 10-K (SEC EDGAR), Johnson & Johnson Investor Relations · Last reviewed July 2026
Johnson & Johnson is a large, diversified healthcare company focused on prescription drugs and medical technology after spinning off its consumer health business (Kenvue) in 2023. The long-term question is whether a deep drug pipeline and steady medical-device demand keep funding its very long record of dividend increases as older drugs lose patent protection.
A broad portfolio of patented drugs and established medical devices, sold into healthcare systems worldwide, produces steady recurring revenue.
Healthcare demand is relatively steady across economic cycles, which supports stable cash flow.
Patents on key drugs expire over time, and generic competition can cut revenue when they do.
Talc litigation tied to the spun-off consumer business has not been fully resolved and could result in significant future settlements. Patent cliffs on key pharmaceuticals could reduce revenue as generics enter markets over the next few years.
The 2023 Kenvue spin-off removed the consumer health business, so year-over-year comparisons around that period can look distorted even though the ongoing business is steadier. Weigh valuation using the company's own filings rather than a third-party estimate.
Pharmaceutical sales growth and how well new drugs offset patents that are expiring.
Educational content only. Market data is delayed and is not financial advice. Always do your own research and consult a licensed professional before investing.